Firstly, it used the latest clinical evidence to evaluate the cost-effectiveness of osimertinib vs. placebo in patients with stage III unresectable EGFR-mutated NSCLC following chemoradiotherapy. Here, EGFR is linked to non-small cell lung carcinoma.